Evidence map›Paper›PMID 40259351›Full record

ArticleBMC complementary medicine and therapies2025

Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model.

Anna Kamlárová, Monika Kvaková, Ľuboš Ambro, René Link, Izabela Bertková, Zdenka Hertelyová, Martin Janíčko, Emília Hijová, Jana Štofilová

Abstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Anna KamlárováCenter of Clinical and Preclinical Research - MediPark, Faculty of Medicine, P. J. Šafárik University, Trieda SNP 1, Košice, 040 11, Slovakia.ORCID http://orcid.org/0000-0001-7871-5338
Monika KvakováCenter of Clinical and Preclinical Research - MediPark, Faculty of Medicine, P. J. Šafárik University, Trieda SNP 1, Košice, 040 11, Slovakia.ORCID http://orcid.org/0000-0002-9659-5584
Ľuboš AmbroCenter for Interdisciplinary Biosciences, Technology and Innovation Park, P.J. Šafárik University, Jesenna 5, Košice, 040 01, Slovakia.ORCID http://orcid.org/0000-0003-4398-1665
René LinkCenter of Clinical and Preclinical Research - MediPark, Faculty of Medicine, P. J. Šafárik University, Trieda SNP 1, Košice, 040 11, Slovakia.ORCID http://orcid.org/0000-0002-3302-2244
Izabela BertkováCenter of Clinical and Preclinical Research - MediPark, Faculty of Medicine, P. J. Šafárik University, Trieda SNP 1, Košice, 040 11, Slovakia.ORCID http://orcid.org/0000-0003-3076-2711
Zdenka HertelyováCenter of Clinical and Preclinical Research - MediPark, Faculty of Medicine, P. J. Šafárik University, Trieda SNP 1, Košice, 040 11, Slovakia.ORCID http://orcid.org/0000-0003-1552-7115
Martin Janíčko2nd Department of Internal Medicine, Faculty of Medicine, P. J. Šafárik University, Trieda SNP 1, Košice, 040 11, Slovakia.ORCID http://orcid.org/0000-0002-3329-3968
Emília HijováCenter of Clinical and Preclinical Research - MediPark, Faculty of Medicine, P. J. Šafárik University, Trieda SNP 1, Košice, 040 11, Slovakia.ORCID http://orcid.org/0000-0002-8259-373X
Jana ŠtofilováCenter of Clinical and Preclinical Research - MediPark, Faculty of Medicine, P. J. Šafárik University, Trieda SNP 1, Košice, 040 11, Slovakia. jana.stofilova@upjs.sk.ORCID http://orcid.org/0000-0002-9409-4153

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-23-0031Agentúra na Podporu Výskumu a Vývoja,Slovakia APVV-16-0176Operational Program Integrated Infrastructure Drive4SIFood 313011V336Operational Program Integrated Infrastructure (OPII) funded by the ERDF PROBIO-3 ITMS2014+: 313011T651
6 · The paper itself

Abstract

backgroundFecal microbiota transplantation (FMT) seems to be a promising approach in ulcerative colitis (UC) management with the aim of repopulating a patient's dysbiotic microbiota with beneficial bacteria and restore its metabolic activity to its healthy characteristics. Metabolites present after FMT may improve the function and integrity of the intestinal barrier, reduce inflammation, and thus induce remission in an UC patient. In this study we evaluated whether the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) model may be a suitable non-invasive alternative for studying and modifying the dysbiotic microbiota in UC by FMT application.

methodsSHIME® model was used to investigate microbial and metabolic changes in the gut microbiota of UC patient induced by FMT application. FMT-modified metabolites from SHIME® were applied to an in vitro model of the intestinal barrier (differentiated Caco-2 and HT-29-MTX-E12 cell lines) compromised by pro-inflammatory cytokines to study the effect of FMT on the intestinal barrier.

resultsQualitative and quantitative microbial analyses showed that FMT increased the diversity and variability of the microbiota in UC patient associated with a significant increase in total bacteria, Bacteroidota and Lactobacillus, as well as an increase in butyrate levels. In addition, an increase in the relative abundance of some important species such as Faecalibacterium prausnitzii and Bifidobacterium longum was observed, and there was also an enrichment of the microbiota with new species such as Blautia obeum, Roseburia faecis, Bifidobacterium adolescentis, Fusicatenibacter saccharivorans and Eubacterium rectale. Furthermore, microbial metabolites modulated by FMT from the SHIME® model prevented intestinal barrier damage and inhibited interleukin 8 (IL-8) and monocyte chemoattractant protein 1 (MCP-1) secretion when cell barriers were pretreated with FMT medium for 24 h. In summary, this study confirmed that a single dose of FMT beneficially modulated the composition and metabolic activity of the UC microbiota in the SHIME® model.

conclusionsFMT favorably modulates the gut microbiota of UC patient cultured in the SHIME® model. FMT-modulated SHIME-derived microbial metabolites improve intact and inflamed intestinal barrier properties in vitro. Repeated applications are necessary to maintain the beneficial effect of FMT in SHIME® model.

Indexed as

Colitis, UlcerativeFecal Microbiota TransplantationGastrointestinal MicrobiomeAdultCaco-2 CellsFemaleHT29 CellsHumansInflammationIntestinal MucosaMaleDysbiosisFecal microbiota transplantationInflammationIntestinal barrierUlcerative colitis

Identifiers

PMID40259351
PMCPMC12013018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.